; however, the interaction between NK cells and tumour targets is poorly understood. The stimulatory lectin-like NKG2D receptor 8±13 is expressed by NK cells, activated CD8 + T cells and by activated macrophages in mice 11 . Several distinct cell-surface ligands that are related to class I major histocompatibility complex molecules have been identi®ed 11±14 , some of which are expressed at high levels by tumour cells but not by normal cells in adults 11, 13, 15, 16 . However, no direct evidence links the expression of these`induced self ' ligands with tumour cell rejection. Here we demonstrate that ectopic expression of the murine NKG2D ligands Rae1b or H60 in several tumour cell lines results in potent rejection of the tumour cells by syngeneic mice. Rejection is mediated by NK cells and/or CD8 + T cells. The ligand-expressing tumour cells induce potent priming of cytotoxic T cells and sensitization of NK cells in vivo. Mice that are exposed to live or irradiated tumour cells expressing Rae1 or H60 are speci®cally immune to subsequent challenge with tumour cells that lack NKG2D ligands, suggesting application of the ligands in the design of tumour vaccines.
As demonstrated by staining with a tetramerized derivative of the extracellular portion of NKG2D, NKG2D ligands are expressed by most of the tumour cells tested, including various lymphoid, myeloid and carcinoma cell lines (ref. 11; and A. Diefenbach and D. Raulet, unpublished data). Northern blot analysis showed that many of the positive cell lines express Rae1 transcripts, whereas H60 transcripts were limited to only one or two of the cell lines tested (data not shown). Rae1 transcripts have not been detected in normal cells from adult mice 15 , suggesting that these genes are speci®cally upregulated in tumour cell lines.
To investigate whether tumour cells that express NKG2D ligands stimulate anti-tumour immune responses, we used a retrovirus expression system to ectopically express high levels of Rae1b or H60 in EL4 (a thymoma), RMA (a T-cell lymphoma) and B16-BL6 (a melanoma). These cell lines are all from C57BL/6 (hereafter termed B6) mice and do not normally express NKG2D ligands 11 . Ligandtransduced cells were selected on the basis of staining with NKG2D tetramers. To serve as controls, tumour cells that were transduced with empty retrovirus vector (designated as EL4/-, B16/-and RMA/-) were selected by genomic polymerase chain reaction (PCR) (see Methods) .
For analysis of the response to EL4 and B16-BL6 tumour cells, groups of ®ve B6 mice were inoculated subcutaneously with syngeneic tumour cell transductants. Control-transduced EL4 or B16-BL6 cells grew progressively at a rate similar to that of untransduced cells (Fig. 1a, c, d , and data not shown), leading to uniform terminal morbidity by about 28 days. Notably, Rae1b-or H60-transduced tumour cells of both types were rejected rapidly and completely, as they failed to yield detectable tumours at any time point (Fig. 1a, c, d) . A tenfold increase in the dose of Rae1b-or H60-transduced EL4 cells (to 5´10 7 cells) did not change the outcome, whereas a higher dose (1´10 5 ) of Rae1b-or H60-transduced B16-BL6 cells resulted in progressive, although substantially delayed, tumour growth in all the mice, compared with the control-transduced tumour cells (data not shown). Ligand-transduced tumour cells of both types also failed to grow in B6 mice that had been depleted of CD8 + T cells or in B6-Rag1 -/-miceÐwhich lack all T and B cellsÐbut grew progressively in normal and B6-Rag1 -/-hosts that had been depleted of NK1.1 + cells (Fig. 1a±e) . Thus, these doses of Rae1b-or H60-transduced EL4 cells and B16-BL6 cells are rejected rapidly by conventional NK cells without a requirement for Tand B cells, including NK1.1 + T cells or gd T cells. Interestingly, Rae1b-or H60-transduced B16-BL6 cells reproducibly exhibited retarded growth in NK-depleted B6-Rag1 -/-mice (Fig.  1e) . It is possible that a residual response against these cells is mediated by non-lymphoid cells such as macrophages, or by small numbers of NK cells that survive antibody treatment.
Rae1b or H60 expression by B16-BL6 cells reduced the frequency of lung metastases by over tenfold after intravenous injection (Fig. 1f) . In another experiment where mice were examined at a later time point, control-transduced B16-BL6 cells formed massive contiguous lung metastases, but ligand-transduced B16-BL6 cells were almost completely rejected (Fig. 1g) . NK1.1 depletion before tumour cell inoculation markedly depressed the rejection of the metastases.
Rae1b-or H60-transduced RMA tumour cells were also rejected by B6 mice (Fig. 2) . Unlike the responses to the other tumour cells, however, the primary rejection of ligand-transduced RMA cells was mediated by both CD8 + T cells and NK cells, although the speci®c outcome depended on the dose of tumour cells. Depletion of both NK1.1 + cells and CD8 + T cells was necessary to abrogate rejection of the smallest inoculum of 10 4 ligand-transduced tumour cells, whereas depletion of either population allowed tumour growth in at least some animals that were injected with the largest dose (10 6 ) of tumour cells (Fig. 2a) . With the intermediate dose of 10 5 tumour cells, depletion of CD8 cells allowed tumour cell growth, but NK cell depletion did not (Fig. 2a) . Thus, either subset is suf®cient for tumour rejection at the lowest tumour cell dose, CD8 cells (but not NK cells) are suf®cient at the intermediate dose, and the two cell types must cooperate to achieve consistent rejection at the highest tumour cell dose. In B6-Rag1 -/-mice, NK cells were suf®cient to reject the Rae1b-or H60-transduced RMA cells at the two lower tumour doses (Fig. 2b) , suggesting that NK cells are more active or effective in these B6-Rag1
-/-mice than in B6 mice. Parallel analysis of mice that were inoculated with the RMA/S cell lineÐa major histocompatibility complex (MHC) class I low version of RMA cellsÐcon®rmed previous reports that these cells are rejected by NK cells and not by CD8 + T cells 2 , and also demonstrated the ef®cacy of our NK cell-depletion procedure (Fig. 2a, b) . Why does NKG2D ligand expression not cause the rejection of most of the tumour cell lines that naturally express these ligands 11 ? In some cases, the host response to the ligands may be overwhelmed by an excess tumour load. Furthermore, the response may critically depend on the levels of NKG2D ligands expressed by tumour cells, especially if the NK cells are also subject to inhibitory signalling by means of MHC-speci®c receptors. Notably, the levels of Rae1b and H60 expression in our transductants were substantially higher than the levels of endogenous NKG2D ligands on most of the naturally expressing tumour cell lines that we tested (Fig. 2c) . Indeed, a comparison of varying ligand levels showed that RMA transductants that had intermediate ligand levels, comparable to most tumour cells 11 ( Fig. 2c , data not shown), were less ef®ciently rejected than were transductants with higher ligand levels (Fig. 2d) . Therefore, the antitumour response to naturally arising tumour cells probably varies depending on the level of NKG2D ligands that are expressed.
To address whether prior immunization with tumour cells that express NKG2D ligands induces protective immunity to ligandnegative tumour cells, mice that had previously rejected Rae1b-or H60-transduced tumour cells (EL4, B16-BL6 or RMA cells) were rechallenged with corresponding ligand-negative tumour cells 8±12 weeks after the ®rst exposure. The ligand-negative tumour cells grew progressively in naive B6 mice, but were rejected by the mice that had been exposed previously to the corresponding Rae1b-or H60-transduced tumour cells (Fig. 3a) . The immunity was speci®c, as mice that had previously rejected ligand-transduced tumour cells of each type were immune only to untransduced tumour cells of the same type (Fig. 3b) . Some delay was observed in the rejection of RMA cells by mice that were primed with ligand-transduced EL4 cells (Fig. 3b) , and this may be in line with evidence indicating a common origin of EL4 and RMA cells 17, 18 . However, the crossprotection was only partial, and was absent or very weak in the reciprocal situation, suggesting that our cell lines have an independent origin, or that most of the response is focused on antigens that are unique to each cell line. We conclude that ligand-expressing tumour cells speci®cally vaccinated the mice against ligand-negative tumour cells of the same type.
Primary rejection of ligand-transduced EL4 and B16-BL6 cells by naive mice was mediated by NK cells (Fig. 1) , but it was not expected that NK cells could provide a speci®c`memory' immune response. Indeed, no immunity to any of the tumour cells developed in Rag1
-/-mice ( Supplementary Information Fig. 1 ). Furthermore, normal mice that were pretreated with anti-CD8 antibody before the initial exposure to all three types of ligandtransduced tumour cells were unable to reject ligand-negative tumour cells on re-challenge (Fig. 3c) , despite the fact that the ligand-transduced tumour cells had been rejected in each case (Figs 1 and 2) . Pretreatment of mice with control immunoglobulin did not alter the memory response to ligand-negative tumour cells. Thus, although CD8 + T cells were not required to reject the primary inoculum of ligand-transduced EL4 and B16-BL6 cells, they were essential for a protective immune response against untransduced tumour cells.
It was possible that immunity arose in this system because NK cell rejection of the transduced tumour cells resulted in excess tumour cell debris, thereby enhancing`crosspriming' of tumour-speci®c CD8 + T cells 19 . Indeed, irradiated untransduced RMA cells, which are expected to die in vivo and yield considerable cell debris, are reportedly effective in vaccinating mice 20 . However, this was not the case with irradiated ligand-negative B16-BL6 tumour cells 21 , as no immunity resulted when mice were vaccinated once or three times in succession with irradiated control-transduced B16-BL6 tumour cells (Fig. 3d) . Mice that were vaccinated in parallel with irradiated ligand-transduced B16-BL6 cells did develop immunity to untransduced tumour cells, suggesting that ligand expression results in priming of tumour-speci®c T cells independent of the generation of cell debris by NK cells. Consistent with this conclusion, irradiated ligand-transduced B16-BL6 cells were effective at priming a tumour-speci®c cytotoxic T-lymphocyte (CTL) response, even in mice that had been previously depleted of NK cells, whereas controltransduced B16-BL6 cells failed to prime CD8 + T-cell responses (see below and Supplementary Information Fig. 2) . Similar results were obtained in the RMA system (Fig. 4) .
Consistent with the role of CD8 + T cells in responses to ligandtransduced tumour cells, irradiated Rae1b-or H60-transduced tumour cells were more effective than ligand-negative tumour cells in priming tumour-speci®c CTLs in vivo, as tested by restimulating with ligand-transduced cells and testing effector function in vitro. Priming with irradiated ligand-transduced RMA cells, for example, increased RMA target cell lysis substantially, and augmented the percentage of RMA-speci®c interferon (IFN)-g producing CD8 + T cells severalfold (Fig. 4a, e) . The effector cells were considerably more active against ligand-transduced RMA cells (Fig. 4b, f) , and this enhancement could be completely blocked with anti-NKG2D antiserum (compare Fig. 4e, g with f, h) , indicating that the NKG2D ligand interaction enhances not only CTL induction in vivo, but also the effector activity of the CTLs. The enhanced induction of CTLs, which were conventional CD8 + NK1.1 -cells (Fig. 4c±f) , occurred even in mice that had been previously depleted of NK1.1 + cells (Fig. 4i) , demonstrating that liganddependent augmentation of the CTL response does not depend directly or indirectly on NK cell activity.
Importantly, the CTLs were tumour-cell speci®c, as they did not lyse any of three other tumour cells (EL4, B16-BL6 or MC38), nor did they lyse Rae1b-transduced B16-BL6 cells (Fig. 4j) . Furthermore, the CTLs did not lyse syngeneic concanavalin A-induced T-cell blasts, suggesting that priming with ligand-transduced tumour cells does not break self-tolerance of CTLs (Fig. 4j) . Highly comparable results were obtained in the B16-BL6 tumour cell system, although the responses were generally weaker, probably because of the low expression of class I MHC molecules by these cells (Supplementary Information Fig. 2) . Similar results were also obtained with CTLs derived from mice that had previously rejected live ligand-transduced tumour cells (data not shown). Thus, tumour cell expression of NKG2D ligands results in a signi®cant enhancement in the priming of tumour-speci®c CTLs in vivo, as well as in the activation of preformed CTLs. These data are in line with evidence that NKG2D engagement co-stimulates human CTL responses in vitro 22 , and extend these ®ndings to in vivo responses to tumour cells.
Induction of NK cell activity in vivo by tumour cells that express Rae1b or H60 was also demonstrable. When inoculated intraperitoneally in naive mice, irradiated Rae1b-or H60-transduced RMA tumour cells increased the number of peritoneal NK cells by 2±4-fold within two days (Fig. 5a) , and substantially enhanced the cytotoxic activity of the cells against YAC-1 target cells (Fig. 5b,  left panel) , whereas control-transduced RMA cells had no effect. A substantially higher fraction of these NK cells also produced IFN-g after in vitro stimulation with YAC-1 tumour cells (Fig. 5c) . As previously reported, class I-de®cient RMA/S cells also induced the local accumulation of NK cells and enhanced their functional activity 23 ( Fig. 5a±c) . In either case, the cytotoxic activity was nearly abolished by pretreatment of effector cells with anti-NK1.1 plus complement or by in vivo depletion of NK1.1 + cells before tumour cell inoculation (Fig. 5b, d) . In contrast, depletion of CD8 + cells before tumour cell inoculation or immediately before the cytotoxicity assay had no effect (Fig. 5b, d) , and similar cytotoxic activity was induced in Rag1
-/-and wild-type mice ( Supplementary  Information Fig. 3) . Thus, the effector cells are conventional NK cells and do not depend on CD8 + cells for their induction. Similar cytotoxicity and cytokine data were obtained with ligand-expressing B16-BL6 and EL4 cells (Supplementary Information Fig. 4) . Therefore, expression of NKG2D ligands, like MHC de®ciency, provokes NK cell recruitment and sensitization in vivo.
A non-depleting anti-NKG2D antiserum injected in vivo almost completely blocked the ligand-dependent induction of NK cytotoxicity and cytokine production against YAC-1 cells (Fig. 5e) . The effect of the antibody was speci®c, as NK cell induction by class Ide®cient RMA/S cells, which do not express NKG2D ligands, was unaffected by the anti-NKG2D antibody. Therefore, the induction process with ligand-transduced cells required interactions with the NKG2D receptor in vivo.
Our results demonstrate that NKG2D ligand expression and consequent activation of NK cells and CD8 + T cells can impose a substantial barrier to the establishment of tumours in vivo. The ligands activate NK cells and T cells through NKG2D, which associates in the membrane with KAP/DAP10Ðan adapter signalling protein that is thought to deliver co-stimulatory signals 10 . It is unknown whether engagement of NKG2D in NK cells results in direct stimulation or supplies a co-stimulatory signal that acts in conjunction with signals from other stimulatory receptors 24, 25 . Nevertheless, NKG2D receptor engagement clearly enhances the effective NK cell response against the three tumour cell lines that we tested. Furthermore, ligand expression by tumour cells also strongly enhanced the generation of tumour-speci®c CD8 T cells. As this enhancement also occurred in mice that were devoid of NK cells (Figs 2a and 4) , and considering that activated CD8 + T cells express NKG2D, we propose that CD8 + T-cell activation is enhanced as a consequence of direct interactions with ligand-expressing tumour cells. It remains possible that the priming of CD8 + T cells is accomplished indirectly as a result of ligand-expressing tumour cells interacting with NKG2D-expressing macrophages 11 . In either case, the results suggest that NKG2D ligands provide an example of innate immune stimuli that function to enhance the adaptive immune response 26 . The effectiveness of ligand transduction of tumour cells in stimulating an anti-tumour response and protective immunity to tumour re-challenge suggests that ligand-expressing cells may have applications in tumour therapy and the development of tumour vaccines. The strong response against B16-BL6 cells is particularly notable in this regard, given that the BL6 variant was selected for high invasiveness and is poorly immunogenic 27 . Indeed, other manipulations such as ectopic B7 expression or CTLA4 blockade do not, by themselves, result in rejection of B16-BL6 cells 28 . The ®nding that typical levels of NKG2D ligands naturally found on most tumour cell lines are suboptimal in inducing antitumour immunity (Fig. 2c, d ) raises the possibility that immunity to such tumours can be boosted by engineering cells with higher levels of ligands. The effectiveness of this approach against preestablished tumours and naturally arising tumours remains to be established.
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Methods
Ectopic expression of NKG2D ligands
Three NKG2D ligand-negative cell lines (EL4, a B6 thymoma; RMA, a B6 T lymphoma derived from the Rauscher virus-induced RBL-5 cell line 2 ; and B16-BL6, a B6 melanoma derived from the B16-F0 cell line 27 ) were retrovirally transduced as described 11 . The retroviral vectors containing the H60 or Rae1b complementary DNAs used for these experiments did not direct synthesis of green¯uorescent protein (GFP) or any other selection marker. Transduced cells expressing equivalent high levels of the NKG2D ligands were sorted after staining with a tetrameric soluble version of NKG2D 
Antibody depletion, tumour inoculation and re-challenge
We used ®ve mice per group for all tumour rejection experiments. C57BL/6J (B6) and B6-Rag1 -/-mice were purchased from Jackson Laboratories, and the B6-Rag1 -/-mice were bred in our animal facilities under speci®c pathogen-free conditions. All mice were used between 8 and 18 weeks of age. NK cells and CD8 + T cells were depleted 28 by intraperitoneal injection of 200 mg monoclonal antibody (PK136 against NK1.1 and 2.43 against CD8) at day -1, 1, 8, 15 and 22. Control mice received the equivalent amounts of normal mouse immunoglobulin-G. Depletions were con®rmed in lymph node and spleen cells 3 weeks after tumour challenge by¯ow cytometry using non-competing antibodies. In general, less than 1.5% of the depleted cell population could be detected in spleen and lymph nodes. Tumour cells were injected subcutaneously in 100 ml PBS in the right¯ank. We monitored tumour development by measuring the tumour size twice weekly with a metric caliper. For the metastasis assay, 3´10 5 B16-BL6 cells were injected intravenously through the tail vein in groups of ®ve mice, and lung metastases were examined 14± 21 days later. For the re-challenge experiments, groups of ®ve mice that had completely rejected the initial tumour (8±12 weeks after initial tumour challenge) were injected in the opposite¯ank with the respective untransduced or control-transduced tumour cells (that is, lacking NKG2D ligands).
Vaccination and ex vivo analysis of CTL activation
Transduced B16-BL6 tumour cells were irradiated (160 Gray (gy)) and 5´10 6 cells were injected, in groups of ®ve mice, in 100 ml PBS subcutaneously in the left¯ank either once at day -10 or three times at day -10, -7 and -4 as indicated. Some mice received injections of unirradiated tumour cells at day -10. At day 0, mice were challenged with 10 4 untransduced B16-BL6 cells in 100 ml PBS in the opposite¯ank. For the ex vivo analysis of CTL activity, groups of ®ve mice received two vaccinations (day 0 and 3) with irradiated (160 gy) RMA or B16-BL6 tumour cell transductants. Two to three weeks after vaccination, mice were killed and pooled splenocytes were restimulated for 5 days with the respective Rae1b-transduced tumour cells. The cells were expanded for another three days before testing cytotoxicity and IFN-g production. In some experiments NK1.1 + or CD8 + T cells were depleted before the cytotoxicity assay by complement (C9)-mediated lysis as described 29 . In vitro blocking of NKG2D was carried out as described previously, using a rat anti-NKG2D antiserum and a control rat serum 11 .
Ex vivo analysis of NK cell activation
Tumour cells were irradiated (120 gy) and injected intraperitoneally as described 23 . We collected peritoneal cells after 72 h (ref. 23) . The percentages (6 s.d.) of NK cells in the peritoneal cavity of individual mice were quanti®ed by¯ow cytometry and electronic gating on lymphocytes (low forward and side light scatter). Peritoneal wash cells were pooled for cytotoxicity and IFN-g assays. In some experiments NK1.1 + or CD8 + T cells were depleted before the cytotoxicity assay by complement-mediated lysis as described 29 .
For the in vivo blocking experiments 100 ml of a non-depleting antiserum speci®c to NKG2D or a control antiserum 11 was injected intraperitoneally. As determined by¯ow cytometry, the antibody did not deplete NK1.1 + cells from the peritoneal cavity (data not shown).
Assays
Cytotoxicity was tested in a standard 4-h 51 Cr release assay 11 . Data are given as the mean of triplicate measurements. Standard deviations were generally less than 5% and are omitted from the ®gures for reasons of clarity. IFN-g production was assayed by stimulating CTLs or NK cells with an equal number of target cells for 5±7 h and staining intracellular IFN-g as described 30 , with gating on CD8 + CD3 + cells or NK1. , but the biochemistry underlying this response remains poorly understood. Here we de®ne a pathway in which increased minute ventilation (V Ç E ) is signalled by deoxyhaemoglobin-derived S-nitrosothiols (SNOs). Speci®cally, we demonstrate that S-nitrosocysteinyl glycine (CGSNO) and S-nitroso-Lcysteine (L-CSNO)Ðbut not S-nitroso-D-cysteine (D-CSNO)Ð reproduce the ventilatory effects of hypoxia at the level of the nucleus tractus solitarius (NTS). We show that plasma from deoxygenated, but not from oxygenated, blood produces the ventilatory effect of both SNOs and hypoxia. Further, this activity is mediated by S-nitrosoglutathione (GSNO), and GSNO activation by g-glutamyl transpeptidase (g-GT) is required. The normal response to hypoxia is impaired in a knockout mouse lacking g-GT. These observations suggest that S-nitrosothiol biochemistry is of central importance to the regulation of breathing.
Failure to increase minute ventilation (V Ç E ) in response to hypoxia may be fatal. In particular, newborn mammals have Figure 1 Glutathione reacts with deoxygenated but not oxygenated blood to form GSNO. Liquid chromatography/mass spectrometry was performed on plasma from blood that was reacted with 400 mM GSH. GSNO was eluted at 5.82 min. The GSNO peak in the deoxygenated blood-derived plasma (blue) was attenuated after ultraviolet treatment (violet) and is not evident in the oxygenated blood-derived plasma (red). Positive identi®cation of the GSNO peak was determined by co-elution of the sample with a GSNO standard. The retention time and both mass spectrometry and mass spectrometry fragmentation pattern of the endogenous species were identical to exogenous GSNO plus the endogenous species. These observations demonstrate that deoxygenated blood reacts with reduced thiol species to form ultraviolet-labile SNO species, whereas oxygenated blood does not.
